Orthocell (ASX:OCC) secured approval to supply its flagship nerve repair device, Remplir, to the United States Department of Defence and Veterans Affairs hospital networks.
The milestone provides the Perth-based company with immediate access to approximately 51 DoD military hospitals and 170 VA medical centres, representing a massive expansion of its commercial footprint in the world's largest healthcare market.
The approval allows Orthocell to leverage its established U.S. distributor network, which currently spans 17 states, to target specialist surgeons operating within these high-volume federal systems.
The move is bolstered by the company’s recent momentum, having already secured 32 Value Analysis Committee approvals for over 115 hospitals, with an additional 57 applications currently pending.
The clinical utility of Remplir in trauma environments has been recently validated through its use in 23 surgical procedures on injured soldiers in Ukraine.
The applications in complex, conflict-related nerve repairs—both primary and secondary—highlight the device’s suitability for the specific trauma profiles encountered within military and veteran healthcare settings.
Management notes that this expansion aligns with a period of accelerating commercialisation and revenue growth.
At the time of reporting, Orthocell's share price was $1.07.